<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2019.94015</article-id><article-id pub-id-type="publisher-id">WJCR-32650</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20190400000_27252451.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  调强放疗治疗TACE后复发或残留PHC的疗效评价
  Efficacy of Intensity-Modulated Radiotherapy for Recurrent or Residual PHC after Transcatheter Arterial Chemoembolization
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姜</surname><given-names>兆祥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>忠超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>翟</surname><given-names>韦玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孟</surname><given-names>俏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>新沂市人民医院，肿瘤放疗科，江苏 新沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>24</day><month>10</month><year>2019</year></pub-date><volume>09</volume><issue>04</issue><fpage>105</fpage><lpage>109</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评价经肝动脉化疗栓塞(TACE)联合调强放疗(IMRT)治疗复发性或残留性原发性肝癌(PHC)的临床疗效和毒性反应。方法：39例接受两次及以上TACE治疗复发或残留的PHC患者，19例进行调强放疗(IMRT)，放疗剂量50~60 Gy/25~30F；20例TACE维持治疗。比较两组治疗前后肿瘤大小和甲胎蛋白(AFP)水平变化、毒副反应及生存期。结果：至随访时IMRT组和TACE组的有效率(CR + PR)和中位生存时间分别为63.2% vs 25.0%和20.2个月vs 13.7个月，差异有统计学意义(P = 0.016和P = 0.021)，IMRT组AFP下降水平明显优于TACE组，不良反应I、II级肝功能损伤高于TACE组。结论：IMRT对TACE治疗后局部复发或残留的PHC患者具有良好的临床疗效，毒性反应可以耐受。
    Objective: To evaluate the clinical efficacy and toxicity of transcatheter arterial chemoembolization (TACE) combined with intensity modulated radiotherapy (IMRT) in recurrent or residual primary hepatocellular carcinoma (PHC). Methods: Thirty-nine PHC patients with recurrence or residual PHC underwent no less than TACE 2 fractions. The nineteen were treated with intensive radiotherapy (IMRT) at a dose of 50 - 60 Gy/25 - 30F and twenty continued TACE therapy. The size of tumor, alpha fetoprotein (AFP) level, toxicities and survival times were assessed after treatment in two groups. Results: Objective response rate (CR + PR) and median survival time of IMRT and TACE group were 63.2% vs 25.0% and 20.2 months vs 13.7 months respectively. The difference was significant (P = 0.016 and P = 0.021). The decrease of AFP was better in the IMRT and adverse reactions of grade I and II liver injury were higher than the TACE. Conclusion: IMRT has a good clinical effect on PHC patients with partial recurrence or residual after TACE, and has acceptable toxicity. 
  
 
</p></abstract><kwd-group><kwd>原发性肝癌，甲胎蛋白，肝动脉栓塞，放射治疗, Primary Hepatocellular Carcinoma</kwd><kwd> Alpha Fetoprotein (AFP)</kwd><kwd> Hepatic Artery Embolization</kwd><kwd> 
Radiotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>调强放疗治疗TACE后复发或残留PHC的疗效评价<sup> </sup></title><p>田 浩，姜兆祥，王忠超，翟韦玉，孟俏</p><p>新沂市人民医院，肿瘤放疗科，江苏 新沂</p><p><img src="//html.hanspub.org/file/1-2150180x1_hanspub.png" /></p><p>收稿日期：2019年10月2日；录用日期：2019年10月17日；发布日期：2019年10月24日</p><disp-formula id="hanspub.32650-formula1"><graphic xlink:href="//html.hanspub.org/file/1-2150180x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：评价经肝动脉化疗栓塞(TACE)联合调强放疗(IMRT)治疗复发性或残留性原发性肝癌(PHC)的临床疗效和毒性反应。方法：39例接受两次及以上TACE治疗复发或残留的PHC患者，19例进行调强放疗(IMRT)，放疗剂量50~60 Gy/25~30F；20例TACE维持治疗。比较两组治疗前后肿瘤大小和甲胎蛋白(AFP)水平变化、毒副反应及生存期。结果：至随访时IMRT组和TACE组的有效率(CR + PR)和中位生存时间分别为63.2% vs 25.0%和20.2个月vs 13.7个月，差异有统计学意义(P = 0.016和P = 0.021)，IMRT组AFP下降水平明显优于TACE组，不良反应I、II级肝功能损伤高于TACE组。结论：IMRT对TACE治疗后局部复发或残留的PHC患者具有良好的临床疗效，毒性反应可以耐受。</p><p>关键词 :原发性肝癌，甲胎蛋白，肝动脉栓塞，放射治疗</p><disp-formula id="hanspub.32650-formula2"><graphic xlink:href="//html.hanspub.org/file/1-2150180x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2150180x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-2150180x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>原发性肝癌(PHC)作为消化系统常见的恶性肿瘤之一，早期PHC的主要治疗手段是外科治疗，早期患者由于临床症状隐匿难以发现，确诊时往往多为中晚期，对于中晚期PHC最主要的治疗方法是肝动脉化学栓塞(TACE) [<xref ref-type="bibr" rid="hanspub.32650-ref1">1</xref>] 。单纯的TACE可以将药物混合栓塞剂碘化油直接注入肿瘤组织，阻断肿瘤的动脉血供并增加肿瘤组织内药物浓度。由于肝脏的供血具有肝动脉、侧枝动脉及门静脉双重供血的特点，即使肿瘤肝动脉被TACE完全栓塞，侧枝动脉及门静脉仍可能为残留的肿瘤细胞提供血液 [<xref ref-type="bibr" rid="hanspub.32650-ref2">2</xref>] ，从而为以后的复发和转移提供了血供来源。因此，本研究旨在评估IMRT治疗TACE术后复发或残留HCC的临床疗效和毒副反应。</p></sec><sec id="s4"><title>2. 材料和方法</title><sec id="s4_1"><title>2.1. 临床资料</title><p>2014年6月至2018年7月，TACE治疗后局部复发或残留原发性肝癌患者39例，平均年龄为55岁(42~75岁)，男性24例、女性15例，19例采取IMRT治疗，20例TACE维持治疗。入选标准如下：1) 病理诊断为肝细胞癌11例，经AASLD标准 [<xref ref-type="bibr" rid="hanspub.32650-ref3">3</xref>] 临床诊断28例；2) 接受TACE至少两次以上；3) 复发和残留诊断标准：在TACE治疗后CT/MR检查，发现肿瘤区碘化油沉积欠佳或肿瘤边缘增长现象定义为肿瘤复发或残余；4) 肝功能Child-Pugh评分A或B级；5) KPS ≥ 80分；6) 正常肝组织体积 &gt; 700 ml；7) 无浸润或淋巴结转移；8) 无腹水征象。在治疗过程中，排除了接受肝肿瘤手术、使用靶向药物或全身化疗的患者。所有患者入组前均签署治疗知情同意书，本研究获得新沂市人民医院伦理委员会批准。</p></sec><sec id="s4_2"><title>2.2. 治疗方法</title><p>放射治疗患者仰卧位，负压真空袋联合体膜固定体位，螺旋CT 1.25 mm层距连续增强扫描定位；飞利浦Pinnacle<sup>3</sup>治疗计划系统进行计划设计，由两名放射肿瘤科医师及物理师共同勾画靶区(GTV)和危及器官(OARs)，以GTV外扩0.5~1 cm为计划靶体积(PTV)的勾画范围，95%的等剂量曲线覆盖靶体积(PTV)，剂量体积直方图(DVH)进行评估并优化放射治疗方案，传输到Elekta公司Precise医用直线加速器按照设定的程序进行治疗。放疗处方剂量：2 Gy/次，共25~30次，5次/W，总剂量50~60 Gy。靶区邻近器官不超过其耐受剂量，平均肝脏剂量 &lt; 23 Gy；接受&gt;30 Gy剂量照射的正常肝脏体积(V30)达到最小化(均&lt;30%)，治疗期间给予常规保肝治疗。</p></sec><sec id="s4_3"><title>2.3. 评价标准</title><p>客观疗效评价按照RECIST1.1 [<xref ref-type="bibr" rid="hanspub.32650-ref4">4</xref>] ，分为完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)，以CR + PR为有效(RR)，CR + PR + SD为获益(DCR)。评价入组治疗前及在IMRT和TACE治疗后3个月AFP水平和肿块大小变化情况。毒副反应按照美国NCICTC标准评价，分为0~IV级。</p></sec><sec id="s4_4"><title>2.4. 统计方法</title><p>采用SPSS 17.0统计学软件进行数据分析及处理，Kaplan-Meier法描绘生存曲线、Log-rank检验比较两组间总生存期(Overall survival OS)的差异，百分比表示客观疗效和毒副反应的发生率，组间比较为X<sup>2</sup>检验，所有P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 疗效</title><p>IMRT组：有效率为63.2% (12/19)高于TACE组的25.0% (5/20)，两组差异有显著性统计学意义(P = 0.016)；IMRT组：11例患者AFP下降到正常范围及治疗前一半，明显优于单纯TACE组25.0% (5/20) (P = 0.037) (表1所示)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the effect between two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >治疗方法</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >CR</th><th align="center" valign="middle" >PR</th><th align="center" valign="middle" >SD</th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >AFP<sub>(</sub><sub>下降至或近正常</sub><sub>)</sub></th><th align="center" valign="middle" >RR</th><th align="center" valign="middle" >P<sub>(RR)</sub></th><th align="center" valign="middle" >P<sub>(AFP)</sub></th></tr></thead><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >63.2% (12/19)</td><td align="center" valign="middle"  rowspan="2"  >0.016</td><td align="center" valign="middle"  rowspan="2"  >0.037</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >25.0% (5/20)</td></tr></tbody></table></table-wrap><p>表1. 两组疗效的对比(%)</p></sec><sec id="s5_2"><title>3.2. 毒副反应</title><p>IMRT组消化道反应6例低于TACE组9例，IMRT组有轻度乏力9例、I和II级肝功能损伤15例多于对照组(表2所示)，两组间差异无显著统计学意义(P = 0.06)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Toxic and side effects in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >毒副反应</th><th align="center" valign="middle"  colspan="4"  >研究组</th><th align="center" valign="middle"  rowspan="2"  >合计(%)</th><th align="center" valign="middle"  colspan="4"  >对照组</th><th align="center" valign="middle"  rowspan="2"  >合计(%)</th></tr></thead><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >I</td><td align="center" valign="middle" >II</td><td align="center" valign="middle" >III</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >I</td><td align="center" valign="middle" >II</td><td align="center" valign="middle" >III</td></tr><tr><td align="center" valign="middle" >骨髓抑制</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >26.3 (5/19)</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >35.0 (7/20)</td></tr><tr><td align="center" valign="middle" >消化道反应</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >21.1 (4/19)</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >45.0 (9/20)</td></tr><tr><td align="center" valign="middle" >肝功能损伤</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >78.9 (15/19)<sup>*</sup></td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >50 (10/20)<sup>*</sup></td></tr><tr><td align="center" valign="middle" >肾功能损伤</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0 (0/19)</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0 (0/20)</td></tr><tr><td align="center" valign="middle" >乏力</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >47.4 (9/19)</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0 (0/20)</td></tr></tbody></table></table-wrap><p>表2. 两组的毒副反应(%)</p><p><sup>*</sup>P = 0.060.</p></sec><sec id="s5_3"><title>3.3. 生存分析</title><p>至随访日研究组和对照组的中位生存时间分别为20.2个月(95% CI：16.4~24.1个月)和13.7个月(95% CI：10.6~16.7个月)，Log Rank检验示两组间P = 0.021，差异有统计学意义(图1所示)；治疗前后AFP水平下降明显的患者生存时间优于下降不显著的患者P = 0.076，差异无显著统计学意义(图2所示)。</p><p>图1. 两组间生存时间曲线(P = 0.021)</p><p>图2. AFP下降水平生存时间曲线(P = 0.076)</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>肝动脉化学栓塞(TACE)是中晚期原发性肝癌(PHC)主要的治疗手段之一，有研究报道 [<xref ref-type="bibr" rid="hanspub.32650-ref5">5</xref>] ，单纯TACE治疗PHC并不能完全控制肿瘤组织，栓塞后的病理学检查显示大约只有22%~50%的肿瘤组织被完全破坏。另外由于肝癌的血供来源于肝动脉、侧枝动脉及门静脉多重供血，肿块直径较大的肝癌患者经TACE后，肿块边缘的仍有侧枝动脉及门静脉参与供血，在一定程度上影响了TACE 的治疗效果，也是单纯TACE治疗后肿块周围继续增长的主要原因之一。对于残余癌或肝癌复发的治疗没有统一的标准，文献 [<xref ref-type="bibr" rid="hanspub.32650-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.32650-ref7">7</xref>] 报道了放射治疗、射频消融、冷冻、微波、酒精等方法，取得的临床效果并不是很满意。有报道 [<xref ref-type="bibr" rid="hanspub.32650-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.32650-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.32650-ref10">10</xref>] SBRT联合TACE对原发性小肝癌治疗优于单纯TACE治疗组，且毒副反应轻微。</p><p>我们对于位于近肝脏边缘处原发性肝癌(最大直径8.5 cm)，在两次或两次以上TACE治疗后影像学检查发现，肿瘤栓塞不完全或肿块边缘有进展的患者可以采用调强放疗(IMRT)作为补充治疗手段。在我们的研究中，TACE联合IMRT组，12、18和24个月生存率分别为78.9% (15/19)、63.2% (12/19)和31.6% (6/19)，中位总生存期为20.2个月。单纯TACE治疗，12、18和24个月生存率分别为50.0% (10/20)、25.0% (5/20)和10.0% (2/20)，中位总生存期为13.7个月。我们还发现在所有患者中治疗前后AFP水平下降显著的患者生存时间要优于下降不显著的患者，差异无显著统计学意义可能与入组的样本量少有关系。在毒副反应方面和相关研究报道 [<xref ref-type="bibr" rid="hanspub.32650-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.32650-ref12">12</xref>] 类似，IMRT组中有9名患者(47.4%)出现1~2级短暂疲劳，6名患者(31.6%)在1个月内出现1~2级胃肠道反应，对症支持治疗症状得到缓解或消除后，所有患者在随访期间未发现因IMRT引起的3级或更高的急性毒性。</p><p>综上所述，IMRT对原发性肝癌是一种的姑息性无创治疗方法，对TACE术后复发或残留的肝癌疗效显著，毒副反应患者可接受。在IMRT治疗后AFP水平下降明显，可能是生存预后的预测因素。</p></sec><sec id="s7"><title>文章引用</title><p>田 浩,姜兆祥,王忠超,翟韦玉,孟 俏. 调强放疗治疗TACE后复发或残留PHC的疗效评价Efficacy of Intensity-Modulated Radiotherapy for Recurrent or Residual PHC after Transcatheter Arterial Chemoembolization[J]. 世界肿瘤研究, 2019, 09(04): 105-109. https://doi.org/10.12677/WJCR.2019.94015</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32650-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">刘合代, 丁罡, 张明, 等. 肝动脉栓塞化疗联合放疗治疗原发性肝癌的疗效分析[J]. 现代肿瘤医学, 2015, 23(9): 1258-1261.</mixed-citation></ref><ref id="hanspub.32650-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">吕江, 陈茂恩, 李冲. 原发性肝癌肝外侧支血供动脉的特点和介入治疗分析[J]. 癌症进展, 2016, 14(7): 703-705.</mixed-citation></ref><ref id="hanspub.32650-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Marrero, J.A., Kulik, L.M., Sirlin, C., Zhu, A.X., et al. (2018) Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 68, 723-750. https://doi.org/10.1002/hep.29913</mixed-citation></ref><ref id="hanspub.32650-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Watanabe, H., Okada, M., Kaji, Y., Satouchi, M., et al. (2009) New Response Evaluation Criteria in Solid Tumours Revised RECIST Guideline (Version 1.1). Japanese Journal of Cancer and Chemotherapy, 36, 2495-2501.</mixed-citation></ref><ref id="hanspub.32650-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Llovet, J.M., et al. (2012) EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 56, 908-943. https://doi.org/10.1016/j.jhep.2011.12.001</mixed-citation></ref><ref id="hanspub.32650-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Shiina, S., Tateishi, R., Arano, T., et al. (2012) Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. American Journal of Gastroenterology, 107, 569-577.  
https://doi.org/10.1038/ajg.2011.425</mixed-citation></ref><ref id="hanspub.32650-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rahimi, R.S. and Trotter, J.F. (2015) Liver Transplantation for Hepatocellular Carcinoma: Outcomes and Treatment Options for Recurrence. Annals of Gastroenterology, 28, 323-330.</mixed-citation></ref><ref id="hanspub.32650-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Honda, Y., Kimura, T., et al. (2013) Stereotactic Body Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Small Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 28, 530-536. 
https://doi.org/10.1111/jgh.12087</mixed-citation></ref><ref id="hanspub.32650-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Su, T.-S., Lu, H.-Z., et al. (2016) Long-Term Survival Analysis in Combined Transarterial Embolization and Stereotactic Bodyradiation Therapy versus Stereotactic Body Radiation Monotherapy for Unresectable Hepatocellular Carcinoma &gt;5cm. BMC Cancer, 16, Article No. 834. https://doi.org/10.1186/s12885-016-2894-9</mixed-citation></ref><ref id="hanspub.32650-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Takeda, A., Sanuki, N., et al. (2016) Phase 2 Study of Stereotactic Body Radiotherapy and Optional Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma Not Amenable to Resection and Radiofrequency Ablation. Cancer, 122, 2041-2049. https://doi.org/10.1002/cncr.30008</mixed-citation></ref><ref id="hanspub.32650-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">芦东徽, 唐隽, 周俊平, 等. 三维适形放射治疗联合经皮肝动脉化疗栓塞不同序贯顺序治疗原发性肝癌伴门静脉癌栓的临床对照[J]. 中华肝脏病杂志, 2015, 23(3): 184-188.</mixed-citation></ref><ref id="hanspub.32650-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">徐海杰, 刘天壤. 原发性肝癌三维适形放射治疗和介入治疗加放疗的疗效比较[J]. 系统医学, 2017, 2(3): 124-126.</mixed-citation></ref></ref-list></back></article>